anpc - ANPC STOCK NEWS

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced that Nasdaq granted an extension for continued listing after a hearing on October 20, 2022. The company must demonstrate compliance with the $1 Bid Price Rule by November 23, 2022, or risk delisting. Previous notices indicated the company's failure to meet this requirement and a lack of sufficient Shareholders’ Equity. AnPac Bio, focusing on early cancer screening, currently has 155 issued patents and operates multiple accredited laboratories.

AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) announced a change in the ratio of its American Depositary Shares (ADSs) to Class A ordinary shares from 1:1 to 1:20, effective November 4, 2022. This action equates to a one-for-twenty reverse ADS split, impacting ADS holders who will need to surrender their certificated ADSs for exchange. Uncertificated ADSs will be automatically converted. While the ADS price is expected to rise proportionally, no guarantees are made regarding its future valuation. AnPac Bio is focused on cancer detection and holds 155 patents as of March 31, 2022.

AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) announced significant changes to its board and management team on October 3, 2022. Mr. Haohan Xu has been appointed Co-Chairperson and Co-CEO, bringing experience from Apifiny Group. Ms. Xiaoyu Li is now the CFO, with a background in investor relations. Other new board members include Mr. Tianruo Pu, Mr. Zhigang Zhao, and Mr. Honggang Tian, each having extensive financial and operational expertise. These appointments aim to drive growth in early cancer screening and detection, continuing development under Dr. Chris Chang Yu.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced a $3.67 million investment from nine investors on September 26, 2022. The investment will enable the purchase of 36.7 million Class A shares through a private offering, expected to close by the end of September 2022. Dr. Chris Yu, Co-CEO, emphasized the importance of this capital for advancing their clinical trials related to cancer detection technology. AnPac Bio is recognized for its significant multi-cancer detection sample size and has 155 patents. The successful trial completion is crucial for commercialization and valuation.

AnPac Bio, a biotechnology firm focused on cancer screening, announced it has filed a request for a hearing with the NASDAQ Hearings Panel. This request arose after a notification from NASDAQ to delist the company’s securities due to non-compliance with the $1 bid price requirement. The company aims to present its financial data and plan to regain compliance in a hearing scheduled for October 20, 2022. The company has not met the $5 million Shareholders’ Equity requirement for a second compliance period.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced on September 12, 2022, that it received a Staff determination letter from Nasdaq, indicating plans to delist its securities due to non-compliance with the $1 bid price rule. Despite being granted 180 days to regain compliance, the company failed to meet the necessary $5 million shareholders’ equity requirement. AnPac Bio intends to appeal the delisting decision, allowing its American Depositary Shares to remain traded during the process. The outcome is uncertain as Nasdaq may not grant the requested suspension or continued listing.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced a significant leadership change on August 2, 2022. Jiawen Kang was appointed to the board of directors and also joined the Audit and Nominating Committees. Yuyang Cui was appointed Co-Chairman and Co-CEO, focusing on capital strategy and business opportunities, while Chris Chang Yu was designated Co-CEO, overseeing general operations. Recent shareholder resolutions resulted in the removal of Aidong Chen and Sheng Liu from the board, reflecting a strategic shift in management.

AnPac Bio-Medical Science Co. (ANPC) announced significant changes in its leadership structure following member resolutions approved on July 14, 2022. The decisions included the immediate removal of Aidong Chen and Sheng Liu as directors. Chris Chang Yu was appointed as both Chief Executive Officer and Chairman of the Board. These changes reflect a shift in governance aimed at improving company direction, particularly in cancer screening and detection technology, where AnPac Bio has established a strong patent portfolio and operational presence in both the U.S. and China.

AnPac Bio-Medical Science Co., Ltd. (ANPC) announced on June 9, 2022, that it has regained compliance with Nasdaq listing requirements, following a hearing panel's decision from May 4, 2022. This compliance is subject to a one-year Mandatory Panel Monitor. As of May 31, 2022, the company's pro forma balance sheet reflected stockholders' equity of $7,442,000, meeting the required minimum of $2.5 million. The company is committed to early cancer screening and detection and holds 155 issued patents, with significant achievements in multi-cancer screening.